Okay. There are clearly very sensitive areas for India, such as pharmaceuticals and generics. I think it will be extremely important that there is absolute clarity about the protocols and procedures that will be followed in processes of certification and regulation in areas of that kind. Simplicity and clarity are going to be extremely important in those sorts of areas.
